Profile data is unavailable for this security.
About the company
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
- Revenue in USD (TTM)0.00
- Net income in USD-71.90m
- Incorporated2019
- Employees28.00
- LocationMineralys Therapeutics Inc150 N. Radnor Chester Road, Suite F200RADNOR 19087United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://mineralystx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verve Therapeutics Inc | 11.76m | -200.07m | 520.11m | 255.00 | -- | 0.8505 | -- | 44.23 | -3.13 | -3.13 | 0.1832 | 7.31 | 0.0164 | -- | 3.40 | 46,109.80 | -27.94 | -- | -29.43 | -- | -- | -- | -1,701.55 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -69.33m | 520.49m | 40.00 | -- | -- | -- | -- | -2.17 | -2.17 | 0.00 | 4.73 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 682.00k | -201.59m | 532.57m | 452.00 | -- | -- | -- | 780.89 | -3.89 | -3.89 | 0.0133 | -1.26 | 0.0024 | -- | -- | 1,508.85 | -69.68 | -83.26 | -78.50 | -93.77 | 75.51 | -- | -29,558.94 | -135,982.00 | 10.22 | -4.91 | 1.20 | -- | -- | -- | -1.96 | -- | -- | -- |
| Compass Pathways PLC (ADR) | 0.00 | -118.46m | 537.17m | 186.00 | -- | 2.16 | -- | -- | -2.39 | -2.39 | 0.00 | 3.64 | 0.00 | -- | -- | 0.00 | -50.06 | -40.85 | -54.08 | -44.48 | -- | -- | -- | -- | -- | -- | 0.113 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Castle Biosciences Inc | 219.79m | -57.47m | 538.22m | 610.00 | -- | 1.37 | -- | 2.45 | -2.15 | -2.15 | 8.20 | 14.27 | 0.488 | 7.55 | 7.12 | 360,308.20 | -12.76 | -9.43 | -14.07 | -10.17 | 79.53 | 80.58 | -26.15 | -28.46 | 6.04 | -- | 0.0003 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Korro Bio Inc | 0.00 | -81.17m | 542.73m | 101.00 | -- | 2.76 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| GH Research PLC | 0.00 | -35.59m | 546.30m | 49.00 | -- | 2.49 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -71.90m | 547.93m | 28.00 | -- | 1.88 | -- | -- | -1.79 | -1.79 | 0.00 | 5.86 | 0.00 | -- | -- | 0.00 | -39.28 | -- | -41.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Olema Pharmaceuticals Inc | 0.00 | -96.66m | 549.64m | 74.00 | -- | 2.13 | -- | -- | -2.16 | -2.16 | 0.00 | 4.62 | 0.00 | -- | -- | 0.00 | -39.24 | -30.06 | -42.54 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| Novavax Inc | 983.71m | -545.06m | 552.81m | 1.54k | -- | -- | -- | 0.562 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Lyell Immunopharma Inc | 130.00k | -234.63m | 559.01m | 224.00 | -- | 0.853 | -- | 4,300.09 | -0.9353 | -0.9353 | 0.0005 | 2.58 | 0.0002 | -- | -- | 580.36 | -27.81 | -- | -29.04 | -- | -- | -- | -180,486.20 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.93m | -64.37m | 567.62m | 25.00 | -- | -- | -- | 293.80 | -0.0573 | -0.0573 | 0.0017 | -0.04 | 0.0653 | -- | -- | 77,280.00 | -211.53 | -381.58 | -- | -- | -- | -- | -3,240.11 | -6,479.25 | -- | -- | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Cabaletta Bio Inc | 0.00 | -67.68m | 570.08m | 101.00 | -- | 2.47 | -- | -- | -1.65 | -1.65 | 0.00 | 4.94 | 0.00 | -- | -- | 0.00 | -36.52 | -33.76 | -39.22 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Zymeworks Inc | 76.01m | -118.67m | 572.31m | 272.00 | -- | 1.23 | -- | 7.53 | -1.74 | -1.74 | 1.10 | 6.57 | 0.1236 | -- | 2.88 | 279,455.90 | -19.30 | -22.58 | -22.01 | -26.90 | -- | -- | -156.13 | -91.17 | -- | -- | 0.0003 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Cogent Biosciences Inc | 0.00 | -192.41m | 574.64m | 164.00 | -- | 2.62 | -- | -- | -2.40 | -2.40 | 0.00 | 2.99 | 0.00 | -- | -- | 0.00 | -62.65 | -49.53 | -70.07 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Data as of Apr 26 2024. Currency figures normalised to Mineralys Therapeutics Inc's reporting currency: US Dollar USD
30.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 12 Feb 2024 | 4.38m | 8.83% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 2.25m | 4.53% |
| Braidwell LPas of 31 Dec 2023 | 2.02m | 4.08% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.29m | 2.59% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 1.17m | 2.35% |
| Laurion Capital Management LPas of 31 Dec 2023 | 1.16m | 2.33% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 958.62k | 1.93% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 743.59k | 1.50% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 699.26k | 1.41% |
| American Century Investment Management, Inc.as of 31 Dec 2023 | 679.26k | 1.37% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
